HRT and GLP-1s: Does Hormone Therapy Boost Weight Loss?

*Educational, not medical advice — reviewed for accuracy against cited sources. Last reviewed: October 21, 2026. Nothing here suggests starting, stopping, switching, or adjusting hormone therapy or any GLP-1 medication, and no article can substitute for your own clinician's judgment. Talk to your clinician before making any change.*

---

The Short Answer

In a large new observational cohort presented at the Menopause Society's 2026 Annual Meeting, menopause hormone therapy use was associated with greater, sustained weight loss on semaglutide. On tirzepatide, an early difference in average weight loss was not statistically significant at later time points. It is an association from a retrospective study, not proof, and weight loss is not a reason to start hormone therapy.

Here is what that means, what earlier research found, why menopause itself changes body composition, and why none of this — including the most encouraging finding — is advice to start, stop, or change anything.

---

What the New Study Found

The data comes from a retrospective cohort study led by Dr. Regina Castaneda of Mayo Clinic Florida, presented at the 2026 Annual Meeting of The Menopause Society in San Diego (October 20–24, 2026), titled "Menopause Hormone Therapy and Weight Loss Response to GLP-1-Based Therapies in Midlife Women."

A note on the evidence tier before anything else: this is a conference presentation, not a peer-reviewed publication. No PMID exists for it yet, and the details may change as the work goes through review. Read it as a signal worth tracking, not a settled result.

What the presentation reported:

• ✦A retrospective observational cohort of nearly 2,400 women on semaglutide and nearly 1,500 on tirzepatide, all 45 or older with a BMI of 27 kg/m² or higher.
• ✦On semaglutide, hormone therapy use was associated with significantly greater and sustained weight loss.
• ✦On tirzepatide, women using hormone therapy initially lost more weight, but the difference in average weight loss was not statistically significant at later time points.

We are not reporting the presentation's effect sizes here: they come from a conference abstract that has not been peer-reviewed, and the numbers may change. The researchers matched each hormone therapy user to two non-users on age, starting BMI, prior obesity-medication use, and type 2 diabetes status, but other differences — in overall health, healthcare access, or engagement with care — cannot be ruled out in a retrospective design. Dr. Castaneda's own framing, via the release: the findings "need to be confirmed in adequately designed prospective trials."

---

What Earlier Research Showed

The new cohort did not appear from nowhere. In the release, Dr. Castaneda notes that the team's earlier, smaller studies showed an association between hormone therapy use and greater weight loss in postmenopausal women. Two published studies from overlapping research groups set the stage.

The smaller semaglutide signal. A 2024 Mayo Clinic retrospective study compared weight-loss response to semaglutide in postmenopausal women with and without hormone therapy use (PMID: 38446869). The hormone therapy group was tiny — 16 women versus 90 without hormone therapy — so read the numbers with that in mind. Total body weight loss was higher with hormone therapy at every checkpoint: about 7% versus 5% at three months, 13% versus 9% at six, 15% versus 10% at nine, and 16% versus 12% at twelve months (p=0.04 at twelve months). The association remained significant after the authors adjusted for potential confounders and held across every checkpoint — but the hormone therapy group was tiny and the design is retrospective, so unmeasured confounding cannot be ruled out, and the authors themselves called for larger studies. One author reported industry consulting income and stock holdings. It is a hypothesis generator, not a verdict.

In one Mayo cohort, women lost more on tirzepatide than men. The same Mayo group published a retrospective analysis of over 1,000 patients who stayed on tirzepatide for at least 12 months, finding that female sex — not age — predicted greater weight loss: women lost about 15.1% versus 10.7% for men at fifteen months (PMID: 42290037). Note what that study does *not* do: it is not an analysis of hormone therapy. It links sex to tirzepatide response; it does not show that estrogen is why.

One additional data point, offered with its limits: a small study comparing semaglutide response in postmenopausal versus premenopausal women found similar percentage weight loss in both groups after four months (5.8% versus 5.1%, not statistically significant) (PMID: 39761057). It was small and did not report results by hormone therapy use — but it is consistent with menopause itself not blocking GLP-1 response.

---

Does Tirzepatide Still Work After Menopause?

Yes — this is the question with the strongest evidence, and the answer is reassuring.

A post hoc analysis of randomized tirzepatide trials (SURMOUNT-1, -3, and -4) grouped participants by reproductive stage (PMID: 40074721). In SURMOUNT-1, weight reduction with tirzepatide versus placebo was roughly 26% versus 2% in premenopausal women, 23% versus 3% in perimenopausal women, and 23% versus 3% in postmenopausal women; 97–98% of tirzepatide participants reached at least 5% weight loss across stages. The authors' conclusion: tirzepatide produces substantial weight reduction irrespective of reproductive stage.

Disclosure: this analysis was funded by Eli Lilly, tirzepatide's manufacturer, and most of its authors are Lilly employees. Post hoc means the subgroup analysis was not the trial's original primary aim. And critically, it did not report results by hormone therapy use — it answers "does menopause blunt tirzepatide?" (no), not "does hormone therapy amplify it?" For how the two drugs compare head to head, see our tirzepatide vs semaglutide comparison.

---

Why Menopause Changes Weight and Body Shape

If you are in perimenopause or early menopause and it feels like your body changed its rules, the physiology agrees with you — but not always the way headlines say.

The Study of Women's Health Across the Nation (SWAN) used imaging and body-composition measures to follow women through the transition (PMID: 30843880). Its key finding is subtle and important: at the start of the menopause transition, the rate of fat gain doubled and lean mass declined, continuing until about two years after the final period — while the rate of *weight* gain showed no discernible change. In other words, the scale may not move much, but the composition underneath it shifts: more fat, less muscle.

Menopause also adds central fat redistribution — the shift toward the abdomen and visceral fat — on top of the weight change that comes with age generally (PMID: 36891919).

This matters for GLP-1 conversations in two ways. First, "GLP-1 and perimenopause" is a real and reasonable question: body composition is actively changing during exactly the years many women start these medications. Second, it means muscle protection deserves explicit attention on a GLP-1 during this window — see our guide to preserving lean mass on a GLP-1.

---

Why Estrogen and GLP-1 Might Interact — So Far, Mostly in Mice

There is a biological reason the association is plausible. In animal research, estrogen and GLP-1 signaling intersect in the brain regions that regulate appetite and energy expenditure.

The proof-of-concept came from an unusual design: researchers chemically linked a GLP-1-mimicking molecule to estrogen so the hormone would be delivered preferentially to GLP-1-targeted neurons in the brain. In mice, this conjugate produced powerful weight-reducing effects (PMID: 23142820). That is mouse research — elegant, and not a human result, and no approved therapy works that way.

A 2026 review of GLP-1 receptor agonists in perimenopause and early postmenopause concluded that "preliminary experimental evidence" suggests "possible complementary effects" between hormone therapy and GLP-1-based therapy — while stating plainly that the efficacy, safety, and interactions of the combination "remain to be determined" (PMID: 42847987).

So: biologically plausible, preliminarily supported in animals, and unproven in people. That is the honest mechanism status.

---

What Experts Say Right Now

The position statements are unambiguous on the decision question, whatever the observational data eventually shows.

The Spanish Menopause Society's 2026 position statement on GLP-1-based therapies notes that semaglutide has the most menopause-specific evidence — still "limited and largely observational" — and calls the hormone therapy × semaglutide association "hypothesis-generating," adding that it should not be used as a reason to initiate hormone therapy solely to augment weight loss (PMID: 42664617). The same statement emphasizes what actually protects midlife women on these therapies: muscle, bone, resistance exercise, and adequate protein.

The North American Menopause Society's 2022 Hormone Therapy Position Statement lists what hormone therapy is actually for: vasomotor symptoms, genitourinary syndrome, and bone-loss prevention, with a benefit-risk balance that is favorable for treating bothersome vasomotor symptoms and preventing bone loss in women under 60 or within ten years of menopause who have no contraindications, and less favorable beyond that window (PMID: 35797481). Weight loss is not among its indications. Hormone therapy decisions are individualized and revisited periodically — a framework that exists for reasons that have nothing to do with GLP-1s.

And Dr. Castaneda herself, via the release: "it's important to remember that weight loss is not an indication for menopause hormone therapy."

---

Already on Both? Safety and Monitoring

Many women take a GLP-1 and hormone therapy at the same time. The new cohort's abstract reports weight outcomes, not safety outcomes, so it does not tell us whether the combination is safe. A 2026 review puts it directly: the safety and interactions of the combination remain to be determined (PMID: 42847987).

If you take both, the practical points are the unglamorous ones: keep both prescribers aware of the full medication picture, and protect muscle and bone deliberately — the position statement's emphasis on resistance exercise and protein (PMID: 42664617) is the actionable core. For the fuller framework on combining GLP-1s with TRT or HRT — interactions, monitoring, and what to flag to your clinician — see our dedicated guide: GLP-1 and TRT/HRT: safety considerations.

---

Questions to Bring to Your Clinician

Not "should I start HRT to lose more weight" — that question starts from the wrong premise. These are the ones that fit the actual evidence:

• ✦Am I a candidate for hormone therapy for my symptoms? Judged on vasomotor symptoms, genitourinary symptoms, bone health, and your individual risk profile — the standard framework (PMID: 35797481), independent of any weight goal.
• ✦Does my hormone therapy use change how we track my GLP-1 results? Worth asking explicitly, given the emerging (and unconfirmed) association.
• ✦How do we protect muscle and bone while I lose weight? Especially relevant across the menopause transition, when lean mass is already declining (PMID: 30843880).
• ✦What would make us change course? Every therapy in this picture gets revisited periodically; agree on the triggers now.

If menopause-stage questions are your main concern, our guide for OB-GYN and reproductive-health questions on GLP-1s covers the broader territory, including perimenopause.

---

Frequently Asked Questions

Does HRT help Ozempic or semaglutide work better? An association, not a proven effect. A large Mayo Clinic–led cohort presented in October 2026 (not yet peer-reviewed) and a smaller published 2024 study both found greater weight loss among hormone therapy users on semaglutide — but both are retrospective, and prospective trials are still needed. "Associated with" is the strongest honest claim.

Does HRT help tirzepatide work better? The new cohort found women on hormone therapy initially lost more on tirzepatide, but the difference in average weight loss was not statistically significant at later time points. The randomized post hoc evidence for tirzepatide across menopause stages did not report results by hormone therapy use.

Should I start hormone therapy to lose more weight on a GLP-1? No. Weight loss is not an indication for hormone therapy, per the study's lead author, the Spanish Menopause Society's 2026 position statement, and the North American Menopause Society's 2022 statement. Hormone therapy decisions are about symptoms, bone, and risk — with your clinician.

Do GLP-1 medicines work after menopause? Yes. Post hoc analysis of randomized tirzepatide trials found large weight reductions versus placebo in pre-, peri-, and postmenopausal women alike, with 97–98% of tirzepatide participants reaching at least 5% weight loss regardless of stage. A small semaglutide study likewise found similar weight loss in pre- and postmenopausal women.

Why is it harder to lose weight during menopause? The transition shifts body composition — the rate of fat gain roughly doubles and lean mass declines — with fat increasingly stored centrally. Notably, the rate of overall weight gain does not clearly change; the composition changes underneath the scale. That makes midlife weight management about composition as much as calories.

Is it safe to take HRT and a GLP-1 together? Many women do, but the studies discussed here measured weight loss, not safety, and a 2026 review concluded the combination's efficacy, safety, and interactions "remain to be determined." That conversation belongs with your clinician, alongside our GLP-1 and TRT/HRT safety considerations guide.

---

Evidence Box

*The headline finding is a conference presentation, not peer-reviewed.*

• ✦Castaneda R et al. (Mayo Clinic Florida), presentation at the 2026 Annual Meeting of The Menopause Society, San Diego, Oct 20–24, 2026 — "Menopause Hormone Therapy and Weight Loss Response to GLP-1-Based Therapies in Midlife Women: A Retrospective Cohort Study." Conference presentation — not peer-reviewed; no PMID yet. Retrospective cohort, ~2,400 semaglutide / ~1,500 tirzepatide users, age 45+, BMI 27+, HT users propensity-matched to non-users. HT associated with greater sustained semaglutide weight loss; tirzepatide difference in average weight loss not statistically significant at later time points.
• ✦PMID: 38446869 — Hurtado MD et al., *Menopause*, 2024. Retrospective cohort (Mayo): 16 women on HT vs 90 without, semaglutide; higher total body weight loss with HT at 3/6/9/12 months; association remained significant after adjustment for confounders; small retrospective cohort, authors call for larger studies.
• ✦PMID: 42290037 — Castaneda R et al., *Obesity*, 2026. Retrospective real-world cohort, 1,039 patients on tirzepatide for ≥12 months: female sex (not age) predicted greater weight loss (15.1% vs 10.7% at 15 months). Not an HT analysis.
• ✦PMID: 40074721 — Tchang BG et al., *Obesity*, 2025. Post hoc analysis of randomized SURMOUNT trials (industry-funded by Eli Lilly): substantial tirzepatide weight reduction vs placebo across pre-, peri-, and postmenopausal stages. Did not report results by HT use (HT/contraceptive use was recorded only as a baseline characteristic).
• ✦PMID: 39761057 — Nicolau J et al., *Metabolic Syndrome and Related Disorders*, 2025. Small observational study: similar percentage weight loss on semaglutide in post- vs premenopausal women at 4 months; no results reported by HT use.
• ✦PMID: 42664617 — Sánchez-Prieto M et al., *Maturitas*, 2026. Position statement (Spanish Menopause Society): semaglutide evidence in menopause "limited and largely observational"; the HT × semaglutide association is hypothesis-generating and should not justify initiating HT for weight loss.
• ✦PMID: 35797481 — The North American Menopause Society, *Menopause*, 2022. Position statement: established HT indications (vasomotor symptoms, genitourinary syndrome, bone loss); weight loss is not among the listed indications; benefit-risk depends on age and time since menopause.
• ✦PMID: 42847987 — Ozcivit Erkan IB et al., *Climacteric*, 2026. Narrative review: "preliminary experimental evidence" suggests possible complementary MHT–GLP-1 effects; efficacy, safety, and interactions of the combination remain to be determined.
• ✦PMID: 23142820 — Finan B et al., *Nature Medicine*, 2012. Preclinical (mouse) study: a GLP-1–estrogen conjugate produced potent weight-reducing effects in mice. Mechanistic plausibility only; not a human result.
• ✦PMID: 30843880 — Greendale GA et al., *JCI Insight*, 2019. Longitudinal cohort (SWAN): rate of fat gain doubled and lean mass declined across the menopause transition; no discernible change in the rate of overall weight gain.
• ✦PMID: 36891919 — Fenton A et al., *Climacteric*, 2023. Narrative review: menopause adds metabolic change and central/visceral fat redistribution on top of age-related weight gain.

---

Talk to a Physician-Led Program

Menopause, hormone therapy, and GLP-1 response all interact with your whole health picture — symptoms, medications, bone and muscle health, and goals. If you want that picture looked at as a whole, talk to a physician-led GLP-1 program about it: our GLP-1 program exists for exactly these conversations, including how menopause fits in.

---

*LuxeFit Wellness is a virtual-only clinic serving patients nationwide. This content is educational only and does not constitute medical advice, and it is not a recommendation to start, stop, switch, or adjust hormone therapy or any GLP-1 medication. Weight loss is not an indication for menopause hormone therapy. Talk to your clinician before making any change.*

*You built it. We optimize it.*

Published by LuxeFit Wellness — physician-led GLP-1 and peptide therapy. Read the LuxeFit Wellness brand guide for programs, pricing, and how it works.

This article is for educational purposes only and does not constitute medical advice. Information on this website should not be used to diagnose, treat, or prevent any medical condition. Consult with a licensed physician before starting any new therapy.